Survival benefit of induction chemotherapy in treatment for stage III or IV locally advanced nasopharyngeal carcinoma – An updated meta-analysis and systematic review

Hu, Tingting; Fang, Lucheng; Shi, Licai; Wang, Wen; Huang, Yideng

doi:10.1016/j.amjoto.2021.102973

Cited by 5 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the treatment side effects and other related profiles are not revealed in the results. However, the current meta‐analytic results reconfirmed the significant benefits for survival of patients with locoregionally advanced NPC seen in previous meta‐analyses 26–35 . Therefore, the benefits of ICT for the survival condition of locoregionally advanced NPC might be consistent and persuasive.…”

Section: Discussionsupporting

confidence: 79%

“…Our meta‐analysis enrolled the latest studies evaluating ICT with CCRT for patients with locoregionally advanced NPC 18,19,24 . The results might be more updated than previous meta‐analyses 26–31 . We also analyzed more survival indicators than the previous meta‐analyses 27–29 .…”

Section: Discussionmentioning

confidence: 99%

“… 18 , 19 , 24 The results might be more updated than previous meta‐analyses. 26 , 27 , 28 , 29 , 30 , 31 We also analyzed more survival indicators than the previous meta‐analyses. 27 , 28 , 29 In addition, our meta‐analysis purely focused on randomized controlled trials, which minimizes bias from retrospective studies or cohort studies as found in other meta‐analyses.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Survival after induction chemotherapy in locoregional advanced nasopharyngeal carcinoma: An updated systematic review and meta‐analysis

Meng,

Huang,

Huang

2023

Laryngoscope Investig Oto

View full text Add to dashboard Cite

BackgroundInduction chemotherapy (ICT) augmentation is a common strategy for standard concurrent chemoradiotherapy (CCRT) of locoregionally advanced nasopharyngeal carcinoma (NPC). The survival condition is a crucial issue for patients with locoregionally advanced NPC. The survival of ICT patients with CCRT treatment versus standard CCRT alone should be elucidated via a systemic review and meta‐analysis of randomized clinical trials.MethodsWe compared ICT with CCRT and CCRT alone treatment to determine if ICT with CCRT can be associated with a significant benefit of survival conditions versus CCRT. Different survival indicators were analyzed for the ICT with CCRT. Twelve studies with a total of 3711 patients with locoregionally advanced NPC were enrolled. The focused outcome was the overall survival, progression‐free survival, distant metastasis‐free survival, and locoregional recurrence‐free survival.ResultsOur results showed that ICT with CCRT is associated with a significant benefit for the overall survival status versus CCRT treatment. Similar significant benefits in the survival condition were seen in progression‐free survival, distant metastasis‐free survival, and locoregional recurrence‐free survival.ConclusionsThe updated meta‐analysis results suggest that the ICT with CCRT might be associated with significant benefits of survival in overall, progression‐free, distant metastasis‐free, as well as locoregional recurrence‐free dimensions versus CCRT treatment. However, the bias of different kinds, doses, and regimens of chemotherapy agents and radiotherapy should not be ignored.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Survival after induction chemotherapy in locoregional advanced nasopharyngeal carcinoma: An updated systematic review and meta‐analysis

Meng,

Huang,

Huang

2023

Laryngoscope Investig Oto

View full text Add to dashboard Cite

show abstract

“…Nghiên cứu này trái ngược với kết quả tiêu cực được báo cáo bởi Tan đã mô tả trước đó. Tất nhiên, có sự gia tăng độc tính liên quan đến điều trị từ liệu pháp hóa trị tân bổ trợ có thể gây nguy cơ cao hơn về giảm bạch cầu trung tính, giảm tiểu cầu, nhiễm độc thận và buồn nôn/nôn [30], [31]. Đến thời điểm hiện tại, chưa có sự đồng thuận cuối cùng nào liên quan đến cường độ tối ưu của các phác đồ hóa trị tân bổ trợ [32].…”

Section: ứNg Dụng Lâm Sàng đIều Trị Ung Thư Vòm Mũi Họng Ebv Dương Tínhunclassified

Epstein Barr Virus Và Ung Thư Vòm Mũi Họng

Ngọc¹,

Phượng²,

Hòa³

et al. 2022

TNUJST

View full text Add to dashboard Cite

Virus Epstein-Barr, được phát hiện năm 1964, đến nay được cho là có liên quan đến nhiều bệnh lý ung thư như ung thư vòm mũi họng, ung thư dạ dày và u lympho ác tính… Mục tiêu của bài tổng quan này tập trung phân tích ưu, nhược điểm của các kỹ thuật xét nghiệm Epstein-Barr virus và ứng dụng trong lâm sàng điều trị các bệnh nhân ung thư vòm mũi họng có Epstein-Barr virus dương tính theo phương châm y học cá thể hóa. Chúng tôi đã tìm kiếm, phân tích, tổng hợp các bài báo liên quan trên Pubmed. Kết quả cho thấy đã và đang có nhiều phương pháp xét nghiệm Epstein-Barr virus từ định tính đến định lượng, với các ưu/nhược điểm khác nhau, trong đó lai tại chỗ và PCR được lựa chọn hơn cả. Việc điều trị ung thư vòm mũi họng có Epstein-Barr virus dương tính vẫn dựa trên xạ trị đơn thuần hoặc xạ trị kết hợp hóa trị, tuy nhiên tải lượng Epstein-Barr virus liên quan tiên lượng bệnh, liệu pháp miễn dịch mới nổi đã có kết quả đầy hứa hẹn. Như vậy, từ kết quả xét nghiệm định lượng đã khuyến nghị các nhà lâm sàng trong thực hành điều trị cũng như tiên lượng bệnh, đặc biệt trong ung thư vòm mũi họng.

show abstract

“…There have been reports of increased treatment-related toxicity from induction therapy followed by CRT compared to that of CRT alone. A recent meta-analysis of randomized clinical trials demonstrated improved survival benefit with IC, but high incidence of toxic reactions and patient discomfort [ 19 ]. In particular, IC may confer a higher risk of neutropenia, thrombocytopenia, nephrotoxicity, and nausea/vomiting [ 16 , 18 , 20 ].…”

Section: Induction Therapymentioning

confidence: 99%

Multimodality Management of EBV-Associated Nasopharyngeal Carcinoma

Pham

Wandrey

et al. 2021

Cancers

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is a rare cancer of the nasopharyngeal mucosa with a specific geographic predisposition. NPC is often associated with Epstein–Barr Virus (EBV) infection and as a result contains many characteristic biomarkers. Treatment of locally-contained NPC is generally achieved through use of radiotherapy (RT), as part of a multimodality treatment regimen. Induction chemotherapy followed by concurrent RT and platinum-based chemotherapy regimen has emerged as the definitive treatment of choice for locoregionally-advanced NPC. Recently, immunotherapy is finding a role in the treatment of recurrent or metastatic NPC. Immune checkpoint blockade therapies targeted against the programmed death-1 (PD-1) receptor have demonstrated efficacy in early phase clinical trials, with ongoing phase III trials in effect. Biomarkers for treatment efficacy remain an ongoing area of investigation, with important prognostic implications on the horizon.

show abstract

Survival benefit of induction chemotherapy in treatment for stage III or IV locally advanced nasopharyngeal carcinoma – An updated meta-analysis and systematic review

Cited by 5 publications

References 36 publications

Survival after induction chemotherapy in locoregional advanced nasopharyngeal carcinoma: An updated systematic review and meta‐analysis

Survival after induction chemotherapy in locoregional advanced nasopharyngeal carcinoma: An updated systematic review and meta‐analysis

Epstein Barr Virus Và Ung Thư Vòm Mũi Họng

Multimodality Management of EBV-Associated Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About